ArticleJournal of virology2025

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.

Sergii V Fedorchenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.